Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.26 USD | +1.80% | +2.07% | -4.86% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an enterprise value anticipated at 3.83 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.86% | 965M | C- | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- INVA Stock
- Ratings Innoviva, Inc.